These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30381297)

  • 1. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
    Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
    Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
    Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
    Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
    Dang X; Zhou D; Meng L; Bi L
    J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
    Sapienza MR; Pileri S
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].
    Shi J; Xu N; Niu Y; Jia SX; Yang CM; Fang MY
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):86-89. PubMed ID: 38527844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling.
    Rethnam M; Tan DQ; Tan SH; Li J; Yokomori R; Li Y; Yang H; Sanda T; Suda T
    Blood Adv; 2022 Sep; 6(18):5330-5344. PubMed ID: 35482445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
    Lim MS; Lemmert K; Enjeti A
    BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Genomic Alterations, Including a Novel
    Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms.
    Small C; Mukerjee S; Jangam D; Gollapudi S; Singh K; Jaye DL; Aung PP; Querfeld C; Yao K; Chisholm KM; Pullarkat S; Wang S; Gru A; Hussaini M; George TI; Ohgami RS
    Int J Lab Hematol; 2023 Oct; 45(5):726-734. PubMed ID: 37282364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
    Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
    Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].
    Sukegawa S; Sakata-Yanagimoto M; Matsuoka R; Momose H; Kiyoki Y; Noguchi M; Nakamura N; Watanabe R; Fujimoto M; Yokoyama Y; Nishikii H; Kato T; Kusakabe M; Kurita N; Obara N; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2018; 59(12):2567-2573. PubMed ID: 30626790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Ceribelli M; Hou ZE; Kelly PN; Huang DW; Wright G; Ganapathi K; Evbuomwan MO; Pittaluga S; Shaffer AL; Marcucci G; Forman SJ; Xiao W; Guha R; Zhang X; Ferrer M; Chaperot L; Plumas J; Jaffe ES; Thomas CJ; Reizis B; Staudt LM
    Cancer Cell; 2016 Nov; 30(5):764-778. PubMed ID: 27846392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.
    Bastidas Torres AN; Cats D; Mei H; Fanoni D; Gliozzo J; Corti L; Paulli M; Vermeer MH; Willemze R; Berti E; Tensen CP
    Genes Chromosomes Cancer; 2020 May; 59(5):295-308. PubMed ID: 31846142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
    Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
    Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation epigenetic modulators to target myeloid neoplasms.
    Sasca D; Guezguez B; Kühn MWM
    Curr Opin Hematol; 2021 Sep; 28(5):356-363. PubMed ID: 34267079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Lane AA
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):589-600. PubMed ID: 32336422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network assessment of demethylation treatment in melanoma: Differential transcriptome-methylome and antigen profile signatures.
    Jiang Z; Cinti C; Taranta M; Mattioli E; Schena E; Singh S; Khurana R; Lattanzi G; Tsinoremas NF; Capobianco E
    PLoS One; 2018; 13(11):e0206686. PubMed ID: 30485296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.